Barclays’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-359
| Closed | -$199 | – | 5467 |
|
|
2022
Q4 | $199 | Sell |
359
-13,293
| -97% | -$11.3K | ﹤0.01% | 5181 |
|
|
2022
Q3 | $16K | Sell |
13,652
-1,033
| -7% | -$1.11K | ﹤0.01% | 4155 |
|
|
2022
Q2 | $9K | Sell |
14,685
-14,246
| -49% | -$10.9K | ﹤0.01% | 4675 |
|
|
2022
Q1 | $34K | Sell |
28,931
-92,037
| -76% | -$110K | ﹤0.01% | 4265 |
|
|
2021
Q4 | $272K | Buy |
120,968
+70,475
| +140% | +$177K | ﹤0.01% | 3456 |
|
|
2021
Q3 | $172K | Buy |
50,493
+24,666
| +96% | +$76K | ﹤0.01% | 3692 |
|
|
2021
Q2 | $78K | Buy |
25,827
+16,610
| +180% | +$52.6K | ﹤0.01% | 3943 |
|
|
2021
Q1 | $30K | Buy |
+9,217
| New | +$30.8K | ﹤0.01% | 4300 |
|
|
2020
Q3 | – | Sell |
-1
| Closed | – | – | 5703 |
|
|
2020
Q2 | $0 | Buy |
+1
| New | +$1 | ﹤0.01% | 6414 |
|
|
2019
Q2 | – | Sell |
-96
| Closed | – | – | 7390 |
|
|
2019
Q1 | $0 | Hold |
96
| – | – | ﹤0.01% | 7433 |
|
|
2018
Q4 | $0 | Hold |
96
| – | – | ﹤0.01% | 7466 |
|
|
2018
Q3 | $0 | Hold |
96
| – | – | ﹤0.01% | 7481 |
|
|
2018
Q2 | $0 | Sell |
96
-15,011
| -99% | -$30.3K | ﹤0.01% | 7388 |
|
|
2018
Q1 | $32K | Sell |
15,107
-31,389
| -68% | -$67.3K | ﹤0.01% | 6210 |
|
|
2017
Q4 | $94K | Buy |
46,496
+45,400
| +4,142% | +$94.2K | ﹤0.01% | 5289 |
|
|
2017
Q3 | $1K | Sell |
1,096
-33,261
| -97% | -$41.3K | ﹤0.01% | 6784 |
|
|
2017
Q2 | $54K | Buy |
34,357
+15,322
| +80% | +$29.6K | ﹤0.01% | 5316 |
|
|
2017
Q1 | $61K | Buy |
19,035
+8,701
| +84% | +$21.4K | ﹤0.01% | 5225 |
|
|
2016
Q4 | $13K | Buy |
10,334
+8,421
| +440% | +$11K | ﹤0.01% | 5817 |
|
|
2016
Q3 | $3K | Sell |
1,913
-13,071
| -87% | -$20.1K | ﹤0.01% | 6168 |
|
|
2016
Q2 | $20K | Buy |
14,984
+14,682
| +4,862% | +$68.7K | ﹤0.01% | 5276 |
|
|
2016
Q1 | $1K | Sell |
302
-772
| -72% | -$4.72K | ﹤0.01% | 6032 |
|
|
2015
Q4 | $8K | Sell |
1,074
-34,246
| -97% | -$295K | ﹤0.01% | 5468 |
|
|
2015
Q3 | $282K | Buy |
35,320
+24,347
| +222% | +$225K | ﹤0.01% | 3847 |
|
|
2015
Q2 | $109K | Buy |
10,973
+8,682
| +379% | +$111K | ﹤0.01% | 4604 |
|
|
2015
Q1 | $29K | Sell |
2,291
-6,950
| -75% | -$106K | ﹤0.01% | 5637 |
|
|
2014
Q4 | $148K | Sell |
9,241
-296,725
| -97% | -$4.32M | ﹤0.01% | 4880 |
|
|
2014
Q3 | $3.98M | Buy |
305,966
+75,435
| +33% | +$898K | ﹤0.01% | 2000 |
|
|
2014
Q2 | $2.77M | Buy |
230,531
+6,660
| +3% | +$69.4K | ﹤0.01% | 2292 |
|
|
2014
Q1 | $2.46M | Buy |
223,871
+44,157
| +25% | +$593K | ﹤0.01% | 2351 |
|
|
2013
Q4 | $2.34M | Buy |
179,714
+5,661
| +3% | +$79.9K | ﹤0.01% | 2506 |
|
|
2013
Q3 | $2.96M | Sell |
174,053
-56,789
| -25% | -$1.09M | ﹤0.01% | 2169 |
|
|
2013
Q2 | $3.74M | Buy |
+230,842
| New | +$7.14M | ﹤0.01% | 1877 |
|
Other funds holding INFI
BI
SFM
CC
E
Barclays's INFI Position: Q1 2023 in Review
Barclays sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 359 shares — an estimated $199 sold.
Barclays first reported a position in INFI in Q2 2013 and held it in 33 quarters. The position peaked at $3.98M in Q3 2014. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.
- Barclays reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Barclays sold 359 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $199.
- Barclays first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 33 quarters.
- Barclays's Infinity Pharmaceuticals, Inc. position peaked at $3.98M in Q3 2014.
- 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.
Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.